Abstract:Abstract Background Metabolic reprogramming is a key feature of cancer cells and is considered a new hallmark of cancer. With our increasing understanding and appreciation of tumor biology and metabolic complexity, targeting or regulating the expression of certain key metabolic enzymes of metabolic reprogramming may be important strategies for tumor therapy. Glycolysis is an essential part of the complex network of glucose metabolism, and hexokinases (HKs) are the key factors of the glycolysis pathway. Although HKs have also received attention in tumors, their roles in tumors are still not fully and systematically explored, particularly in immunization. Methods Through using multiple online datasets, including the TCGA database, Genecards database, CellMiner database, and Deepscreening database, and combining multiple algorithms, the association of HKs with prognosis, Tumor microenvironment (TME), Tumor immunity, and drug sensitivity were investigated. HKs were also evaluated for their prognostic relevance to specific tumor types and their synergistic effects by constructing prognostic HKs signatures. In particular, the deep learning algorithm predicted the active molecules binding to HKs. Results Cox and survival analysis suggested that HKs were significant factors influencing tumor progression. HKs expression levels strongly correlated with TME, RNAss, and Tumor immunity. Their influences varied in diverse tumors or some specific tumor types. In addition, the relationship between gene expression of HKs and drug sensitivity was investigated, and the results suggested the potential of targeting HKs, especially HKDC1 to improve drug resistance. Furthermore, a validation screen of drug prediction and molecular docking obtained several molecules targeting HKs. Finally, the roles of HKs were confirmed in Brain Lower Grade Glioma (LGG) and Acute Myeloid Leukemia (LAML) by constructing the HKs signatures, further, their homogeneity and heterogeneity were elaborated. Conclusion Our systematic study revealed the significant roles of HKs in tumorigenesis and metastasis, as well as their impact and diverse correlations on tumor immune and metabolic activity. The clinical application of HKs is a viable target and offers the new clinical prospects, especially in the development of personalized medicines for the treatment of LGG and LAML.

Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma

HMGB3 is Associated With an Unfavorable Prognosis of Neuroblastoma and Promotes Tumor Progression by Mediating TPX2

Hexokinase 3 Dysfunction Promotes Tumorigenesis and Immune Escape by Upregulating Monocyte/macrophage Infiltration into the Clear Cell Renal Cell Carcinoma Microenvironment

Hepatocyte Nuclear Factor 4 Alpha Promotes the Invasion, Metastasis and Angiogenesis of Neuroblastoma Cells Via Targeting Matrix Metalloproteinase 14.

Exploring the Prognostic Value of HK3 and Its Association with Immune Infiltration in Glioblastoma Multiforme

Identification of the key roles of different hexokinases on the diagnosis, prognosis, tumor immunity, drug response: evidence from pan-cancer analysis and construction prognostic HKs signatures

METTL3-induced lncARSR aggravates neuroblastoma tumorigenic properties through stabilizing PHOX2B

Downregulation of MEG3 and Upregulation of EZH2 Cooperatively Promote Neuroblastoma Progression.

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma

Retraction Note: HNF4A-AS1/hnRNPU/CTCF Axis As a Therapeutic Target for Aerobic Glycolysis and Neuroblastoma Progression.

LncRNA HCP5 Promotes Neuroblastoma Proliferation by Regulating Mir-186-5p/map3k2 Signal Axis.

Overexpression of HMGA1 Deregulates Tumor Growth Via Cdc25a and Alters Migration/invasion Through a Cdc25a-Independent Pathway in Medulloblastoma

CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma

Molecular profiling of core immune-escape genes highlights TNFAIP3 as an immune-related prognostic biomarker in neuroblastoma

HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

A Novel Druggable Dual-Specificity tYrosine-Regulated Kinase3/Calmodulin Kinase-like Vesicle-Associated Signaling Module with Therapeutic Implications in Neuroblastoma

Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma

Identification and Characterization of a Glucometabolic Prognostic Gene Signature in Neuroblastoma based on N6-methyladenosine Eraser ALKBH5

KCNK3 inhibits proliferation and glucose metabolism of lung adenocarcinoma via activation of AMPK-TXNIP pathway

Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.